bioRxiv Science⌕ Search

Biology subjects

Sjodahl, G.

Publications and source records attributed to Sjodahl, G..

3 recordsLinked to original sources

CD44v6 Drives Tumor Aggressiveness and Chemoresistance in Bladder Cancer

Bladder cancer is a fast-moving and recurrent malignancy where survival hinges on early detection and precise risk stratification. The search for robust biomarkers is urgent, and CD44v6 has emerged as a compelling candidate. In this study, we reveal that CD44v6 is not merely a marker but a driver of urothelial carcinoma aggressiveness. Through integrated clinical and functional analyses, we show that high CD44v6 expression is strongly associated with poor patient outcomes. Mechanistic investigations demonstrate that CD44v6 amplifies the proliferative, migratory, and invasive potential of bladder cancer cells, while conferring marked resistance to cisplatin. These findings position CD44v6 at the intersection of tumor progression and therapeutic failure, underscoring its value as both a prognostic biomarker and a promising therapeutic target. Targeting CD44v6 could pave the way for strategies that curb disease aggressiveness and overcome chemoresistance in bladder cancer.

cancer biology↗

A versatile and upgraded version of the LundTax classification algorithm applied to independent cohorts

Stratification of cancer into biologically and molecularly similar subgroups is a cornerstone of precision medicine and transcriptomic profiling has revealed that urothelial carcinoma (UC) is a heterogeneous disease with several distinct molecular subtypes. The Lund Taxonomy classification system for urothelial carcinoma aims to be applicable across the whole disease spectrum including both non-muscle invasive and invasive bladder cancer. For a classification system to be useful it is of critical importance that it can be applied robustly and reproducibly to new samples. Many transcriptomic methods used for subtype classification are affected by the choice of expression platform, data preprocessing, cohort composition, and tumor purity. The application of a subtype classification system across studies therefore comes with a degree of uncertainty regarding whether the predictions in a new cohort accurately recapitulate the originally intended stratification. Currently, only limited data has been published evaluating the transferability and applicability of existing stratification systems and their respective classification-algorithms to external datasets. In the present investigation we develop a single sample classifier based on in-house microarray and RNA-sequencing data intended to be broadly applicable across datasets, studies, and tumor stages. We evaluate the performance of the proposed method and the Lund Taxonomical classification across 10 published bladder cancer cohorts (n=2560 cases) by examining the expression of characteristic subtype associated gene signatures, and whether complementary data such as mutations, clinical outcomes, response, or variant histologies are captured by our classification. Effects of varying sample purity on the classification results were also evaluated by generating low-purity versions of samples in silico. We show that the classifier is robustly applicable across different gene expression profiling platforms and preprocessing methods, and less sensitive to variations in sample purity. The classifier is available as the LundTaxonomy2023Classifier R package on GitHub.

bioinformatics↗

The consensus molecular classification of muscle-invasive bladder cancer

Muscle-Invasive Bladder Cancer (MIBC) is a molecularly diverse disease with heterogeneous clinical outcomes. Several molecular classifications have been proposed, yielding diverse sets of subtypes, which hampers the clinical implications of such knowledge. Here, we report the results of a large international effort to reach a consensus on MIBC molecular subtypes. Using 1750 MIBC transcriptomes and a network-based analysis of six independent MIBC classification systems, we identified a consensus set of six molecular classes: Luminal Papillary (24%), Luminal Non-Specified (8%), Luminal Unstable (15%), Stroma-rich (15%), Basal/Squamous (35%), and Neuroendocrine-like (3%). These consensus classes differ regarding underlying oncogenic mechanisms, infiltration by immune and stromal cells, and histological and clinical characteristics. This consensus system offers a robust framework that will enable testing and validating predictive biomarkers in future clinical trials.

cancer biology↗